Idexx stock fell Monday despite beating fourth-quarter expectations and issuing strong guidance for 2026.

We came across a bullish thesis on IDEXX Laboratories, Inc. on MTC’s Substack. In this article, we will summarize the bulls’ ...

Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water ...

Fidelity Investments, an investment management company, recently released its “Fidelity Growth Strategies Fund” ...

IDEXX Laboratories Inc. (NASDAQ: IDXX) reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast on Monday.

The Q4 earnings report for IDEXX Laboratories (NASDAQ: IDXX) was released on Monday, February 2, 2026 at 06:30 AM. Here's ...

IDEXX Laboratories, Inc. IDXX is well-poised to grow in the upcoming quarters due to the strong momentum in its CAG (Companion Animal Group) Diagnostics business. The company is also growing its ...

IDEXX beat Q4 expectations, but weak vet visit trends and softer guidance pressured shares. Click here to find out why IDXX ...

Revenue for Q4 2024 was reported at $954 million, surpassing the estimate of $935 million. Q4 EPS came in at $2.62, exceeding the anticipated $2.40. The Companion Animal Group diagnostics segment ...

Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The fund focuses on ...

While they might not represent the most exciting field in the biotech space, animal healthcare companies have been a steady, consistent source of growth in what's often a turbulent market. One company ...